KANSAS CITY, Kan., June 19, 2017 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that Shane J. Schaffer, PharmD, Chairman and Chief Executive Officer of Cingulate Therapeutics, will present at the 2017 Biotechnology Innovation Organization International Convention held on June 19-22 in San Diego.
|
Date: |
Wednesday, June 21, 2017 | |
|
Time: |
1:30 PM (Pacific Time) | |
|
Location: |
Theater 4, San Diego Convention Center, San Diego, CA |
About Cingulate Therapeutics
Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents and adults. CTX-1301 and CTX-1302 utilize an innovative, flexible core tableting technology with a Target Product Profile designed to deliver a rapid onset, last the entire active day, and minimize the afternoon crash with minimal impact on sleep and appetite. The Company has initiated Proof of Concept Phase I clinical trials and plans to implement the full clinical plan for both CTX-1301 and CTX-1302 in early 2018. Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information visit www.cingulatetherapeutics.com.
For Investors & Media:
Tiberend Strategic Advisors, Inc.
Jonathon Brzezinski, Ph.D.: jbrzezinski@tiberend.com; (212) 375-2681
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150
SOURCE Cingulate Therapeutics, LLC